François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi’s Executive Committee effective April 1, 2024. He will be based in Paris and will succeed Jean-Baptiste de Chatillon who will step down from his role to become…
According to the European Cancer Information System, 31% of men and 25% of women are expected to be diagnosed with cancer in the European Union before reaching the age of 75. The latest study from the European Patent Office finds…
Synthekine Inc., an engineered cytokine therapeutics company, today announced a worldwide collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. The collaboration will focus on advancing Synthekine’s multiple approaches to optimizing IL-10, with…
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who…
Supported by the Singapore Economic Development Board (EDB), the Digital Hub aims to propel advancements within the healthcare and semiconductor industries. Singapore is recognized globally for driving innovation and digital excellence, particularly in key areas such as digital health, semiconductor…
Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Tyruko® (natalizumab) in Germany from February 1. Developed by Polpharma Biologics, Tyruko® is the first and only biosimilar to treat RRMS. Tyruko® is indicated as a…
Pfizer and Astellas Pharma announced that on January 26 the European Medicines Agency (EMA) validated for review a Type II variation application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients…
FDA has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only medicine approved in the U.S. specifically indicated to…
AbbVie strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network. Located in…
Akouos, a wholly owned subsidiary of Eli Lilly and Company, announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history…